Literature DB >> 15715080

Molecular genetic analysis of oligodendroglial tumors.

Christian Hartmann1, Wolf Mueller, Ulrike Lass, Suzanne Kamel-Reid, Andreas von Deimling.   

Abstract

Deletions on the short arm of chromosome 1 (1p) and the long arm of chromosome 19 (19q) are molecular hallmark lesions of oligodendroglial tumors. Ever since oligodendroglial tumors with 1p and 19q deletions were shown to respond to chemotherapy, neuropathologists have been facing increasing requests for such molecular analysis. Therefore, there is increasing demand for reliable and simple assays. This brief report compiles information on different technical approaches, including manual and automated loss of heterozygosity analysis, fluorescence in situ hybridization techniques, and quantitative polymerase chain reaction. Herein we present a detailed protocol describing loss of heterozygosity analysis with microsatellite markers currently in use for two multicenter studies.

Entities:  

Mesh:

Year:  2005        PMID: 15715080     DOI: 10.1093/jnen/64.1.10

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  17 in total

Review 1.  Molecular diagnostics: techniques and recommendations for 1p/19q assessment.

Authors:  Adelheid Woehrer; Johannes A Hainfellner
Journal:  CNS Oncol       Date:  2015-11-06

Review 2.  Malignant glioma: neuropathology and neurobiology.

Authors:  Matthias Preusser; Christine Haberler; Johannes A Hainfellner
Journal:  Wien Med Wochenschr       Date:  2006-06

3.  Age at diagnosis and loss of heterozygosity on chromosome 1p and 19q in oligodendroglial tumors.

Authors:  M Hergersberg; L Mariani; E Vassella; C Murtin; J Weis; M Moschopulos; H Laeng; H Landolt; A Huber; U Roelcke
Journal:  J Neurooncol       Date:  2006-05-10       Impact factor: 4.130

4.  18F-FET-PET as a biomarker for therapy response in non-contrast enhancing glioma following chemotherapy.

Authors:  Bogdana Suchorska; Marcus Unterrainer; Annamaria Biczok; Marketa Sosnova; Robert Forbrig; Peter Bartenstein; Jörg-Christian Tonn; Nathalie Lisa Albert; Friedrich-Wilhelm Kreth
Journal:  J Neurooncol       Date:  2018-06-08       Impact factor: 4.130

Review 5.  Biology, genetics and imaging of glial cell tumours.

Authors:  C Walker; A Baborie; D Crooks; S Wilkins; M D Jenkinson
Journal:  Br J Radiol       Date:  2011-12       Impact factor: 3.039

6.  Correlation of histomorphologic prognostic markers and proliferative index with loss of heterozygosity 1p/19q and MGMT status in diffusely infiltrating gliomas.

Authors:  Prabal Deb; N S Mani; S M Sudumbrekar; Nitin Taneja; Seema Patrikar
Journal:  Med J Armed Forces India       Date:  2012-12-01

7.  Temozolomide and 13-cis retinoic acid in patients with anaplastic gliomas: a prospective single-arm monocentric phase-II study (RNOP-05).

Authors:  Oliver Grauer; Christina Pascher; Christian Hartmann; Florian Zeman; Michael Weller; Martin Proescholdt; Alexander Brawanski; Thorsten Pietsch; Wolfgang Wick; Ulrich Bogdahn; Peter Hau
Journal:  J Neurooncol       Date:  2011-03-04       Impact factor: 4.130

8.  Analysis of IDH1-R132 mutation, BRAF V600 mutation and KIAA1549-BRAF fusion transcript status in central nervous system tumors supports pediatric tumor classification.

Authors:  Midea Gierke; Jan Sperveslage; David Schwab; Rudi Beschorner; Martin Ebinger; Martin U Schuhmann; Jens Schittenhelm
Journal:  J Cancer Res Clin Oncol       Date:  2015-06-27       Impact factor: 4.553

9.  Chromosomal alterations in oligodendroglial tumours over multiple surgeries: is tumour progression associated with change in 1p/19q status?

Authors:  B A Campbell; D E Horsman; J Maguire; S Young; D Curman; R Ma; B Thiessen
Journal:  J Neurooncol       Date:  2008-05-06       Impact factor: 4.130

10.  Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas.

Authors:  Nesrin Sabha; Christiane B Knobbe; Majula Maganti; Soha Al Omar; Mark Bernstein; Rob Cairns; Besmira Çako; Andreas von Deimling; David Capper; Tak W Mak; Tim-Rasmus Kiehl; Philippe Carvalho; Evelyn Garrett; Arie Perry; Gelareh Zadeh; Abhijit Guha
Journal:  Neuro Oncol       Date:  2014-07       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.